Grant: Fellowship - PA: Respiratory Health - CIHR/CLA/GSK
University of Calgary
$56,250.00
cAMP-Dependent gene transactivation: a novel mechanism underlying the anti-inflammatory activity of PDE4 inhibitors in COPD.
FY 2011-12
Summary
Chronic obstructive pulmonary disease (COPD) is a chronic disease of the lungs that includes bronchitis (excessive mucus production) & emphysema (lung destruction). COPD takes a long time to develop, affects middle aged and elderly people and is caused, usually, by chronic cigarette smoking. Worryingly, it is the only cause of death that is increasing worldwide and it is predicted that it will be the third leading cause of death by 2020. Currently, COPD is a huge health issue that is under-recognized, under-diagnosed and under-reported. Until very recently, COPD could not be well treated. However, in November 2010 Health Canada approved a new medicine, called roflumilast, which is a phosphodiesterase (PDE) 4 inhibitor, for people with severe COPD. Clinical trials have shown roflumilast to be clinically effective although side effects have also been reported. However, what currently is unknown is how PDE4 inhibitors work in COPD. Accordingly, understanding the mechanism of action of these new medicines is the primary aim of this project. We will adopt a multidisciplinary approach-using lung taken from normal human subjects and patients with COPD. In COPD, one of the typical findings is the presence of inflammation in the lungs, which is related to disease severity. The primary aims of this project are to determine the effects of PDE4 inhibitors on the expression of genes that can inhibit the inflammation found in COPD and to dissect out the biological machinery inside cells that are used by these new medicines to activate these genes. These studies should provide a clear picture of how PDE4 inhibitors work in COPD. We believe that roflumilast "switches on" a variety of genes in the human lung that inhibits the processes that produce COPD. By understanding how roflumilast and other PDE4 inhibitors work in COPD will allow "better roflumilasts" to be made. Such an advance could provide an effective means of managing a lung disease that has reached pandemic proportions.
Department
Program
Fellowship - PA: Respiratory Health - CIHR/CLA/GSK
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
243239
Name
Sharma Pawan
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
GlaxoSmithKline (Mississauga, Ontario); Canadian Lung Association (Ottawa)
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
cAMP-Dependent gene transactivation: a novel mechanism underlying the anti-inflammatory activity of PDE4 inhibitors in COPD.
Programtype2
Fellowship Programs
Orgnameinp2
University of Calgary
Cihramount2
$56,250
Cihrequipment2
$0
Programname2
Fellowship - PA: Respiratory Health - CIHR/CLA/GSK
Keyworddelim
Chronic Obstructive Pulmonary Disease; Epithelial Cells; Gene Transactivation; Phosphodiesterase 4; Roflumilast
Abstract
Chronic obstructive pulmonary disease (COPD) is a chronic disease of the lungs that includes bronchitis (excessive mucus production) & emphysema (lung destruction). COPD takes a long time to develop, affects middle aged and elderly people and is caused, usually, by chronic cigarette smoking. Worryingly, it is the only cause of death that is increasing worldwide and it is predicted that it will be the third leading cause of death by 2020. Currently, COPD is a huge health issue that is under-recognized, under-diagnosed and under-reported. Until very recently, COPD could not be well treated. However, in November 2010 Health Canada approved a new medicine, called roflumilast, which is a phosphodiesterase (PDE) 4 inhibitor, for people with severe COPD. Clinical trials have shown roflumilast to be clinically effective although side effects have also been reported. However, what currently is unknown is how PDE4 inhibitors work in COPD. Accordingly, understanding the mechanism of action of these new medicines is the primary aim of this project. We will adopt a multidisciplinary approach-using lung taken from normal human subjects and patients with COPD. In COPD, one of the typical findings is the presence of inflammation in the lungs, which is related to disease severity. The primary aims of this project are to determine the effects of PDE4 inhibitors on the expression of genes that can inhibit the inflammation found in COPD and to dissect out the biological machinery inside cells that are used by these new medicines to activate these genes. These studies should provide a clear picture of how PDE4 inhibitors work in COPD. We believe that roflumilast "switches on" a variety of genes in the human lung that inhibits the processes that produce COPD. By understanding how roflumilast and other PDE4 inhibitors work in COPD will allow "better roflumilasts" to be made. Such an advance could provide an effective means of managing a lung disease that has reached pandemic proportions.
Competitiondate
201110
Approvedterm2
2 yrs 6 mths
Pinamesdelim
Sharma, Pawan
Approvedterm
2 ans 6 mois
Cihrcontribution2
Patient Oriented Research~ $33,750~ $0~~ $22,500~ $0~